Biomarin Pharmaceutical Inc (BMRN)

80.98
0.06 0.07
NASDAQ : Health Care
Prev Close 80.92
Open 80.99
Day Low/High 80.84 / 81.41
52 Wk Low/High 62.12 / 148.92
Volume 111.25K
Avg Volume 1.32M
Exchange NASDAQ
Shares Outstanding 175.27M
Market Cap 14.19B
EPS -3.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

My three top predictions for the next six months.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

Cramer: These Sectors Look Bullish (Part III)

Cramer: These Sectors Look Bullish (Part III)

From Abbott Labs to Wynn, these names rate checking out.

Cramer: There Are Powerful Themes in Several Bull Markets

Cramer: There Are Powerful Themes in Several Bull Markets

It's a wonder to me how split this market really is.

Your Game Plan for Next Week: Cramer's 'Mad Money' Recap (Friday 4/28/17)

Your Game Plan for Next Week: Cramer's 'Mad Money' Recap (Friday 4/28/17)

It's been a heavy week for earnings, but Jim Cramer is already looking ahead to next week -- and Apple.

Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year

Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year

Brineura is first and only treatment for CLN2 disease, a form of Batten disease.

I'm Big on Housing Entering Quarter No. 2

I'm Big on Housing Entering Quarter No. 2

Home builders make up the second-largest allocation in my portfolio, behind biotech.

Short Interest Increases 10.3% For BMRN

Short Interest Increases 10.3% For BMRN

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 793,152 share increase in total short interest for BioMarin Pharmaceutical Inc. , to 8,456,120, an increase of 10.35% since 12/15/2016.

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Johnson & Johnson Looks for New Deal That's Just Right

Johnson & Johnson Looks for New Deal That's Just Right

Actelion was too pricey. Now J&J is looking for another acquisition.

BioMarin Surging Beneath the Surface

BioMarin Surging Beneath the Surface

The pharmaceutical stock is about to go from sideways to up.

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

Here are Monday's top research calls, including upgrades for Biogen and Time Warner, and downgrades for GoPro and L Brands.

BioMarin Pharmaceutical Becomes #19 Most Shorted Nasdaq 100 Component, Replacing Dish Network

BioMarin Pharmaceutical Becomes #19 Most Shorted Nasdaq 100 Component, Replacing Dish Network

The most recent short interest data has been released for the 10/14/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.

Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics

Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics

Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.